Emerging Growth Equities, Ltd. Initiates Coverage of Sarepta Therapeutics, Inc. (SRPT) With a BUY Rating and $38.00 Price

  Emerging Growth Equities, Ltd. Initiates Coverage of Sarepta Therapeutics,
            Inc. (SRPT) With a BUY Rating and $38.00 Price Target

PR Newswire

KING OF PRUSSIA, Pa., March 11, 2013

KING OF PRUSSIA, Pa., March 11, 2013 /PRNewswire/ --Emerging Growth Equities,
Ltd. initiates coverage of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) with a
BUY rating and a $38.00 price target. Sarepta Therapeutics, Inc. focuses on
the discovery and development of RNA-based therapeutics for the treatment of
rare and infectious diseases.

Emerging Growth Equities, Ltd., is a specialty brokerage and investment
banking firm that provides high quality distribution, research and trade
execution for institutional and retail clients. Emerging Growth Equities,
Ltd. specializes in fulfilling the capital requirements of well-managed
emerging growth companies.

Institutional investors may call their Emerging Growth Equities, Ltd. sales
person for a full text of the report at 610-783-1800.

This publication is neither an offer to sell nor a solicitation to buy any
securities mentioned herein. The information contained herein is based on data
obtained from recognized sources that are believed to be reliable. Emerging
Growth Equities, Ltd. has not independently verified the facts, assumptions
and estimates contained in this report. Accordingly, no representation or
warranty, expressed or implied, is made as to, and no reliance should be
placed on, the fairness, accuracy, completeness or correctness of the
information and opinions contained in this report. The information contained
in this report is not and does not purport to be a complete analysis of every
material fact respecting any company, industry, or security.

Most of the companies Emerging Growth Equities, Ltd. follows are emerging and
mid-sized growth companies whose securities typically involve a higher degree
of risk and more volatility than the securities of more established
companies. For these and other reasons, the investments discussed or
recommended in this report may be unsuitable for investors depending on their
specific investment objectives and financial position. Transactions in
securities mentioned herein may be effected only in those states where such
securities are qualified for sale.

Any statements nonfactual in nature herein constitute only current opinions or
estimates, represent only the current judgment of the author(s), and are
subject to change without notice. This report contains forward-looking
statements, which involve risks and uncertainties. Actual results may differ
significantly from the results described in the forward-looking statements.
Emerging Growth Equities, Ltd. (or one of its affiliates) or their partners,
officers, directors, analysts, employees or customers may have an interest in
the securities mentioned herein and may make purchases or sales as principal
or agent of these securities, or their derivatives, while this report is in
circulation. A partner, employee, analyst, officer, or director of Emerging
Growth Equities, Ltd. (or one of its affiliates) may serve as a director or
consultant for any company mentioned herein. Emerging Growth Equities, Ltd.
(or one of its affiliates) may from time to time perform investment banking
services for, or solicit investment banking business or other business from,
any company mentioned herein. Additional information on the securities
discussed herein is available on request. © Copyright 2013 Emerging Growth
Equities, Ltd.

Emerging Growth Equities, Ltd. is a member of the Financial Industry
Regulatory Authority, CRD number 47040.

Contact: Debjit Chattopadhyay, Ph.D., MBA
         Director of Research
         610-783-4782 or 888-293-1800



SOURCE Emerging Growth Equities, Ltd.
 
Press spacebar to pause and continue. Press esc to stop.